Nasus Pharma

OrganisationROR

Trials

NCT07228325
Phase 1/2, Enrolling by invitation, 50 people, 14 Nov 2025
NCT07045701
Phase 2/3, Enrolling by invitation, 30 people, 1 Jul 2025
NCT06205134
Phase 1/2, Completed, 12 people, 12 Jan 2024
NCT04696822
Phase 1, Completed, 12 people, 6 Jan 2021